SCHEMBL2467154

SCHEMBL2467154

CCc1ccc(CCNC(=O)C2(Cc3ccccc3)CCN(C(=O)COc3ccccc3)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 1/20 0.48
USP2 O75604 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.46
THRB P10828 1/20 0.46
GHSR Q92847 1/20 0.46
KDM4E B2RXH2 1/20 0.45
PTPN1 P18031 1/20 0.45
POLB P06746 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
GPR183 P32249 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2471698 0.94 MEN1 (0.48) FKBP1AUSP2GAAKMT2AMEN1
SCHEMBL2474188 0.90 KMT2A (0.51) FKBP1AUSP2GAAKMT2AMEN1
SCHEMBL2469565 0.90 CYP2D6 (0.50) USP2KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL2471735 0.87 NPC1 (0.49) FKBP1AKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL2470205 0.87 ALDH1A1 (0.51) FKBP1AKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL2467982 0.85 MEN1 (0.42) FKBP1AGAAKMT2AMEN1SMN1; SMN2
SCHEMBL2469275 0.85 MAPT (0.54) GAAKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL2467181 0.84 KMT2A (0.56) USP2GAAKMT2AMEN1SMN1; SMN2
SCHEMBL2470362 0.84 CYP2D6 (0.45) FKBP1AGAAKMT2AMEN1ALDH1A1
SCHEMBL2471827 0.84 ALDH1A1 (0.45) FKBP1AKMT2AMEN1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 FKBP1A 1791/4885USP2 2057/4885GAA 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.